Nondominant CD8+ T cells are active players in the vaccine-induced antitumor immune response

Journal of Immunology

Volumn 186, Issue 7, 2011, Pages 3847-3857

  Uram, Jennifer N ^a,b   Black, Chelsea M ^a,b   Flynn, Emilee ^a,b   Huang, Lanqing ^a,b   Armstrong, Todd D ^a,b   Jaffee, Elizabeth M ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; PC 61; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR IMMUNITY; WHOLE CELL;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NIH 3T3 CELLS; RATS; RECEPTOR, ERBB-2;

EID: 79955012459     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000361     Document Type: Article

References (66)

1. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352. (Pubitemid 24181083)
2. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181: 2109-2117.
3. Chen, W., and J. McCluskey. 2006. Immunodominance and immunodomination: Critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95: 203-247. (Pubitemid 44066527)
4. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11: 729-766. (Pubitemid 23115022)
5. Yewdell, J. W. 2006. Confronting complexity: Real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543. (Pubitemid 44529047)
6. Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J. P. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602. (Pubitemid 40723662)
7. Dutoit, V., V. Rubio-Godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Liénard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A10254-262: High avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61: 5850-5856. (Pubitemid 32769104)
8. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994. (Pubitemid 29035425)
9. Lewis, J. D., B. D. Reilly, and R. K. Bright. 2003. Tumor-associated antigens: From discovery to immunity. Int. Rev. Immunol. 22: 81-112. (Pubitemid 36758540)
10. Cibotti, R., J. M. Kanellopoulos, J. P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a selfprotein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89: 416-420.
11. Grossmann, M. E., T. Davila, and T. Celis. 2001. Avoiding tolerance against prostatic antigenswith subdominant peptide epitopes. J. Immunother. 24: 237-241. (Pubitemid 32479714)
12. Zehn, D., and M. J. Bevan. 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25: 261-270. (Pubitemid 44224142)
13. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651. (Pubitemid 28049303)
14. Scardino, A., D. A. Gross, P. Alves, J. L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L. M. Nadler, F. A. Lemonnier, et al. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 168: 5900-5906. (Pubitemid 34556179)
15. Cordaro, T. A., K. E. de Visser, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2002. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 168: 651-660. (Pubitemid 34049565)
16. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569-3576. (Pubitemid 30482178)
17. Lyman, M. A., C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman. 2005. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J. Immunol. 174: 2563-2572. (Pubitemid 40279669)
18. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89: 10578-10582.
19. Murata, S., B. H. Ladle, P. S. Kim, E. R. Lutz, M. E. Wolpoe, S. E. Ivie, H. M. Smith, T. D. Armstrong, L. A. Emens, E. M. Jaffee, and R. T. Reilly. 2006. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. 176: 974-983. (Pubitemid 43099696)
20. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/ neu tolerized mice. Cancer Res. 61: 3689-3697. (Pubitemid 32694981)
21. Ercolini, A. M., J. P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170: 4273-4280. (Pubitemid 36428195)
22. Manning, E. A., J. G. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens. 2007. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13: 3951-3959. (Pubitemid 47037603)
23. Jaffee, E. M., M. C. Thomas, A. Y. Huang, K. M. Hauda, H. I. Levitsky, and D. M. Pardoll. 1996. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol. 19: 176-183. (Pubitemid 26234611)
24. Schulz, M., P. Aichele, R. Schneider, T. H. Hansen, R. M. Zinkernagel, and H. Hengartner. 1991. Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. Eur. J. Immunol. 21: 1181-1185.
25. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer- Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. (Pubitemid 26332731)
26. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17: 317-329. (Pubitemid 47211967)
27. Beattie, T., R. Kaul, T. Rostron, T. Dong, P. Easterbrook, W. Jaoko, J. Kimani, F. Plummer, A. McMichael, and S. Rowland-Jones. 2004. Screening for HIVspecific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS 18: 1595-1598. (Pubitemid 39037485)
28. Kitano, M., N. Kobayashi, Y. Kawashima, T. Akahoshi, K. Nokihara, S. Oka, and M. Takighuchi. 2008. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect. 10: 764-772.
29. Martin, P., P. Parroche, L. Chatel, C. Barretto, A. Beck, C. Trépo, C. Bain, Y. C. Lone, G. Inchauspé, and A. Fournillier. 2004. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. J. Med. Virol. 74: 397-405. (Pubitemid 39281637)
30. Todd, R. W., J. C. Steele, I. Etherington, and D. M. Luesley. 2004. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. Gynecol. Oncol. 92: 167-174. (Pubitemid 38147386)
31. Singh, R., and Y. Paterson. 2006. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res. 66: 7748-7757. (Pubitemid 44289235)
32. Singh, R., and Y. Paterson. 2007. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER- 2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol. Immunother. 56: 927-938. (Pubitemid 46723584)
33. Singh, R., and Y. Paterson. 2007. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 67: 1887-1892. (Pubitemid 46424202)
34. Rock, K. L., and L. Shen. 2005. Cross-presentation: Underlying mechanisms and role in immune surveillance. Immunol. Rev. 207: 166-183. (Pubitemid 41415016)
35. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317. (Pubitemid 38697426)
36. Shen, X., S. B. Wong, C. B. Buck, J. Zhang, and R. F. Siliciano. 2002. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J. Immunol. 169: 4222-4229. (Pubitemid 35178193)
37. Donohue, K. B., J. M. Grant, E. F. Tewalt, D. C. Palmer, M. R. Theoret, N. P. Restifo, and C. C. Norbury. 2006. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119: 63-73. (Pubitemid 44201156)
38. Berche, P., J. L. Gaillard, and P. J. Sansonetti. 1987. Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. J. Immunol. 138: 2266-2271. (Pubitemid 17046282)
39. Brunt, L. M., D. A. Portnoy, and E. R. Unanue. 1990. Presentation of Listeria monocytogenes to CD8+ T cells requires secretion of hemolysin and intracellular bacterial growth. J. Immunol. 145: 3540-3546.
40. Schnupf, P., and D. A. Portnoy. 2007. Listeriolysin O: A phagosome-specific lysin. Microbes Infect. 9: 1176-1187. (Pubitemid 47375145)
41. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class Irestricted tumor antigens. Science 264: 961-965. (Pubitemid 24196166)
42. Thomas, A. M., L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y. C. Chen, L. Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee. 2004. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo crosspriming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200: 297-306. (Pubitemid 39031249)
43. Stier, E. M., M. Mandal, and K. D. Lee. 2005. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol. Pharm. 2: 74-82. (Pubitemid 40314732)
44. Wick, M. J., and H. G. Ljunggren. 1999. Processing of bacterial antigens for peptide presentation on MHC class I molecules. Immunol. Rev. 172: 153-162. (Pubitemid 30000476)
45. Kim, P. S., T. D. Armstrong, H. Song, M. E. Wolpoe, V. Weiss, E. A. Manning, L. Q. Huang, S. Murata, G. Sgouros, L. A. Emens, et al. 2008. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 118: 1700-1711. (Pubitemid 351632374)
46. Dhodapkar, K. M., J. Krasovsky, B. Williamson, and M. V. Dhodapkar. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195: 125-133. (Pubitemid 34074502)
47. den Haan, J. M., and M. J. Bevan. 2002. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8+ and CD82 dendritic cells in vivo. J. Exp. Med. 196: 817-827.
48. Yewdell, J. W. 2005. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol. Rev. 207: 8-18. (Pubitemid 41415004)
49. Belz, G. T., W. Xie, and P. C. Doherty. 2001. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J. Immunol. 166: 4627-4633. (Pubitemid 32233749)
50. Liu, Y., S. Daley, V. N. Evdokimova, D. D. Zdobinski, D. M. Potter, and L. H. Butterfield. 2006. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J. Immunol. 177: 712-721. (Pubitemid 43939186)
51. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234. (Pubitemid 29288845)
52. Hernández, J., P. P. Lee, M. M. Davis, and L. A. Sherman. 2000. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164: 596-602. (Pubitemid 30043678)
53. Dutoit, V., V. Rubio-Godoy, M. A. Doucey, P. Batard, D. Liénard, D. Rimoldi, D. Speiser, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2002. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168: 1167-1171. (Pubitemid 34094481)
54. Derby, M. A., J. Wang, D. H. Margulies, and J. A. Berzofsky. 2001. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13: 817-824. (Pubitemid 32514707)
55. Rubio-Godoy, V., V. Dutoit, D. Rimoldi, D. Lienard, F. Lejeune, D. Speiser, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Discrepancy between ELISPOT IFN-g secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/ MHC complexes half-life. Proc. Natl. Acad. Sci. USA 98: 10302-10307. (Pubitemid 32803015)
56. Villacres, M. C., S. F. Lacey, C. Auge, J. Longmate, J. M. Leedom, and D. J. Diamond. 2003. Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity. J. Infect. Dis. 188: 908-918. (Pubitemid 37176039)
57. La Gruta, N. L., S. J. Turner, and P. C. Doherty. 2004. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: Correlation of cytokine profile and TCR avidity. J. Immunol. 172: 5553-5560. (Pubitemid 38542057)
58. Moore, T. V., G. E. Lyons, N. Brasic, J. J. Roszkowski, S. Voelkl, A. Mackensen, W. M. Kast, I. C. Le Poole, and M. I. Nishimura. 2009. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol. Immunother. 58: 719-728.
59. Andreansky, S. S., J. Stambas, P. G. Thomas, W. Xie, R. J. Webby, and P. C. Doherty. 2005. Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses. J. Virol. 79: 4329-4339. (Pubitemid 40388370)
60. Kedzierska, K., C. Guillonneau, S. Gras, L. A. Hatton, R. Webby, A. W. Purcell, J. Rossjohn, P. C. Doherty, and S. J. Turner. 2008. Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy. Proc. Natl. Acad. Sci. USA 105: 19408-19413.
61. Zehn, D., S. Y. Lee, and M. J. Bevan. 2009. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458: 211-214.
62. Alexander-Miller, M. A. 2005. High-avidity CD8+ T cells: Optimal soldiers in the war against viruses and tumors. Immunol. Res. 31: 13-24. (Pubitemid 40065421)
63. Laheru, D., E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al. 2008. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14: 1455-1463. (Pubitemid 351413929)
64. Disis, M. L., and M. A. Cheever. 1997. HER-2/neu protein: A target for antigenspecific immunotherapy of human cancer. Adv. Cancer Res. 71: 343-371.
65. Dobaño, C., A. McTague, A. Sette, S. L. Hoffman, W. O. Rogers, and D. L. Doolan. 2007. Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+ T cell mediated protective immunity against malaria. Mol. Immunol. 44: 2235-2248. (Pubitemid 46097114)
66. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 59: 3128-3133. (Pubitemid 29316012)